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Abstract
Background: In Poland, gonorrhoea has been a mandatorily reported infection since 1948, however, the reported
incidences are likely underestimated. No antimicrobial resistance (AMR) data for Neisseria gonorrhoeae has been
internationally reported in nearly four decades, and data concerning genetic characteristics of N. gonorrhoeae are totally
lacking. The aims of this study were to investigate the AMR to previously and currently recommended gonorrhoea
treatment options, the main genetic resistance determinant (penA) for extended-spectrum cephalosporins (ESCs),
and genotypic distribution of N. gonorrhoeae isolates in Poland in 2010-2012.
Methods: N. gonorrhoeae isolates cultured in 2010 (n = 28), 2011 (n = 92) and 2012 (n = 108) in Warsaw and Bialystok,
Poland, were examined using antimicrobial susceptibility testing (Etest), pyrosequencing of penA and N. gonorrhoeae
multi-antigen sequence typing (NG-MAST).
Results: The proportions of N. gonorrhoeae isolates showing resistance were as follows: ciprofloxacin 61%, tetracycline
43%, penicillin G 22%, and azithromycin 8.8%. No isolates resistant to ceftriaxone, cefixime or spectinomycin were
found. However, the proportion of isolates with an ESC MIC = 0.125 mg/L, i.e. at the resistance breakpoint, increased
significantly from none in 2010 to 9.3% and 19% in 2012 for ceftriaxone and cefixime, respectively. Furthermore, 3.1%
of the isolates showed multidrug resistance, i.e., resistance to ciprofloxacin, penicillin G, azithromycin, and decreased
susceptibility to cefixime (MIC = 0.125 mg/L). Seventy-six isolates (33%) possessed a penA mosaic allele and 14 isolates
(6.1%) contained an A501V/T alteration in penicillin-binding protein 2. NG-MAST ST1407 (n = 58, 25% of isolates) was
the most prevalent ST, which significantly increased from 2010 (n = 0) to 2012 (n = 46; 43%).
Conclusions: In Poland, the diversified gonococcal population displayed a high resistance to most antimicrobials
internationally previously recommended for gonorrhoea treatment and decreasing susceptibility to the currently
recommended ESCs. The decreasing susceptibility to ESCs was mostly due to the introduction of the internationally
spread multidrug-resistant NG-MAST ST1407 in 2011. It is essential to promptly revise the gonorrhoea treatment
guidelines, improve the gonorrhoea laboratory diagnostics, and implement quality assured surveillance of gonococcal
AMR (ideally also treatment failures) in Poland.
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Background
Infections caused by Neisseria gonorrhoeae are major
public health problems globally. In 2008, the World
Health Organization (WHO) estimated 106 million new
cases of gonorrhoea among adults worldwide, which
represents a 21% increase since 2005 [1]. In 2011, 39
179 gonorrhoea cases were reported from 28 European
Union (EU)/European Economic Area (EEA) countries
(data were not available from Germany and Liechtenstein),
with an overall incidence of 12.6 cases per 100,000 popula-
tion [2]. N. gonorrhoeae has developed antimicrobial re-
sistance (AMR) to all drugs previously recommended for
treatment of gonorrhoea. Extended-spectrum cephalospo-
rins (ESCs) are the only remaining options for first-line
empiric antimicrobial monotherapy in many countries
worldwide [3-6]. However, verified treatment failures with
particularly cefixime [7-13] but also rarely with ceftriaxone
have been reported from several countries [14-18]. The
first extensively-drug resistant (XDR) [3] gonococcal
strains with high-level ESC resistance were also described
recently [9,17,19]. In this worrying situation, the WHO
[20], European Centre for Disease Prevention and Control
(ECDC) [21] and Centers for Disease Control and Preven-
tion (CDC), USA [22] have published action/response
plans to mitigate the spread of multidrug-resistant gonor-
rhoea. A key component in these action/response plans is
to substantially enhance the surveillance of gonococcal
AMR worldwide. The European gonorrhoea treatment
guideline was also revised in 2012, now recommending
treatment with ceftriaxone 500 mg plus azithromycin 2 g
[23]. Mutations in the penA gene (mosaic gene or A501
mutations) encoding the penicillin-binding protein 2
(PBP2) is the main determinant for decreased susceptibil-
ity and resistance to ESCs [5,9,17,24-30]. For molecular
epidemiological typing of gonococci, the N. gonorrhoeae
multiantigen sequence typing (NG-MAST) has been used
in many countries [31].
In the EU country Poland, gonorrhoea has been a
mandatorily reported infection since 1948, when the in-
cidence was approximately 180 cases per 100,000 inhabi-
tants. Since 1970 (incidence of 153), the incidence has
almost annually declined (with exception of from the
mid- to late-1970s). The incidence of gonorrhoea from
1970 to 2012 in Poland is presented in Figure 1. Briefly,
the incidence declined below 100 (87.6) in 1981, below
10 (9.7) in 1992, and below two in 2000. In 2012, the
incidence was 1.9 (Figure 1). Data on the gonorrhoea in-
cidence are available from annual reports; previously
published by the former Institute of Venereology (cur-
rently, Chair and Department of Dermatology and
Venereology, Warsaw, Poland), but since 1998 also by
the National Institute of Public Health (www.pzh.gov.pl).
Since 1974, procaine penicillin 4.8 million units intra-
muscularly together with the uriosuric drug probenecid
1.0 g orally have been recommended for treatment of
gonorrhoea in Poland. Nevertheless, in practice a wide
variety of antimicrobials are in use, i.e., particularly cef-
triaxone (250-500 mg), but also cefixime, azithromycin,
fluoroquinolones or tetracyclines [32,33]. A substantial
proportion of cases are not diagnosed and treated by
dermatovenereologists but, instead, by primary care phy-
sicians, urologists and gynaecologists, mainly private
health care providers. In general, sensitive methods such
as culture or nucleic acid amplification tests (NAATs)
for detection of N. gonorrhoeae are rather rarely used in
Poland. No AMR data for N. gonorrhoeae isolates from
Poland, with exception of β-lactamase production, have
been internationally reported since the 1970s [34-38].
Furthermore, no other phenotypic or genetic character-
istics of gonococcal strains circulating in Poland have
been published.
The aims of this study were to investigate the AMR to
previously and currently recommended treatment op-
tions (to provide an evidence base for revision of the
national treatment guidelines), the main genetic ESC re-
sistance determinant (penA), and genotypic distribution
of N. gonorrhoeae isolates in Poland in 2010-2012.
Methods
Neisseria gonorrhoeae isolates
N. gonorrhoeae isolates (n = 228) were obtained at the
out-patient clinic of the Chair and Department of
Dermatology and Venereology, Medical University of
Warsaw, Poland (n = 218) and in two out-patients’ clinics
in Bialystok, Poland (n = 10) in October 2010–December
2012. In total, 28 (in 2010), 92 (in 2011) and 108
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Figure 1 Incidence of gonorrhoea in Poland in 1970-2012
(number of cases per 100,000 inhabitants). Based on data from
annual reports published by the National Institute of Public Health
(www.pzh.gov.pl), the Former Institute of Venereology, and personal
communication with Iwona Rudnicka, Chair and Department of
Dermatology and Venereology, Medical University of Warsaw,
Warsaw, Poland.
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cultured mainly from consecutive symptomatic gonor-
rhoea patients: 29 females and 199 males. Mean age for
the females was 27 years (median age: 28 years; range:
17-40 years) and for the males 32 years (median age: 30
years; range: 17-74 years). One-hundred-eighty-eight
(82.5%) isolates were obtained from specimens from
male urethra, 28 (12.3%) from cervix, six (2.6%) from
pharynx (from five males and one female) and six (2.6%)
from male rectum.
All isolates were cultured on a modified Thayer-
Martin selective agar media and subsequently confirmed
as N. gonorrhoeae by identification of Gram negative
diplococci in microscopy, rapid oxidase reaction, rapid
sugar utilization test [39] and the PhadeBact GC Mono-
clonal test (Bactus AB, Solna, Sweden), and subsequently
preserved as previously described [40]. All gonococcal
isolates were cultured and stored as part of the routine
diagnostics (standard care) and no patient identification
information was used in the study. The isolates were
later shipped on dry ice to the WHO Collaborating
Centre for Gonorrhoea and other STIs, Sweden for fur-
ther analysis. The 2008 WHO N. gonorrhoeae reference
strains [41] were used for quality control of all pheno-
typic and molecular characterisation.
Antimicrobial susceptibility testing
The minimum inhibitory concentration (MIC; mg/L) of
cefixime, ceftriaxone, penicillin G, azithromycin, cipro-
floxacin, spectinomycin, tetracycline and gentamicin
were analysed using the Etest method on Difco GC
Medium Base agar supplemented with 1% Isovitalex
(bioMerieux AB, Solna, Sweden), according to the in-
structions from the manufacturer. All results were inter-
preted using whole MIC dilutions and where available,
breakpoints for susceptibility (S) and resistance (R) ac-
cording to The European Committee on Antimicrobial
Susceptibility Testing (EUCAST [www.eucast.org]) were
used (Table 1). For gentamicin, no breakpoints are stated
by any organization. β-lactamase production was identi-
fied with nitrocefin discs.
Isolation of genomic DNA
Bacterial DNA was isolated in the robotized NorDiag
Bullet instrument (NorDiag ASA Company, Oslo, Norway)
using the BUGS’n BEADS™ STI-fast kit (NorDiag ASA
Company, Oslo, Norway), according to the instructions
from the manufacturer.
Molecular epidemiological typing
N. gonorrhoeae multiantigen sequence typing (NG-MAST)
was performed as previously described [41,42]. NG-MAST
allele numbers of the more variable segments of porB and
tbpB, and sequence types (STs) were assigned using the
NG-MAST website (www.ng-mast.net).
Sequencing of the main ESC resistance determinant
(penA)
Pyrosequencing of parts of the penA gene was per-
formed as previously described [43].
Sequence alignments
Multiple-sequence alignments of nucleotide sequences
and the deduced amino acid sequences were performed
in the software BioEdit Sequence Alignment Editor ver-
sion 7.0.9.0 with manual adjustment.
Statistical analysis
Statistical analysis was performed using the Statistica
software version 9.0 PL (StatSoft Corporation, Cracow,
Poland). Z-test for comparison of proportions was used.
The level of significance was set at P < 0.05.
Results
Antimicrobial susceptibility of N. gonorrhoeae isolates
(n = 228) in Poland
The results of the antimicrobial susceptibility testing of
all isolates are summarized in Table 1.
Briefly, the overall proportions of isolates with resist-
ance were as follows: ciprofloxacin 60.5%, tetracycline
43.0%, penicillin G 22.4%, and azithromycin 8.8%. The
susceptibility to all those antimicrobials declined from
2010 to 2012, which was also statistically significant for
tetracycline (P < 0.05) and azithromycin (P < 0.05). No
isolates resistant to ceftriaxone, cefixime or spectino-
mycin were identified, and the MICs of gentamicin
were relatively low (Table 1). Seven (3.1%) of the isolates
showed multidrug resistance, i.e., resistance to ciprofloxa-
cin, penicillin G, azithromycin, and decreased susceptibil-
ity to cefixime (MIC= 0.125 mg/L). The overall number of
beta-lactamase producing N. gonorrhoeae isolates was 12
(5.3%), and the proportion of those significantly declined
from 2010 to 2012 (P < 0.05) (Table 1).
Despite that no isolates resistant to ceftriaxone or
cefixime (MIC > 0.125 mg/L) were identified, the propor-
tion of isolates with ESC MICs ≤ 0.016 mg/L decreased
significantly, from 78.6% (n = 22 in 2010) to 36.1%
(n = 39 in 2012) for ceftriaxone (P < 0.05) and from
89.3% (n = 25 in 2010) to 36.1% (n = 39 in 2012) for
cefixime (P < 0.05). Furthermore, the proportion of iso-
lates with an ESC MIC = 0.125 mg/L (the EUCAST
breakpoint for resistance) increased significantly, from
none in 2010, to one (1.1%) and seven (7.6%) in 2011,
and to 10 (9.3%) and 21 (19.4%) in 2012 for ceftriaxone
and cefixime, respectively (P < 0.05). Isolates with an
ESC MIC of 0.125 mg/L have resulted in treatment fail-
ures with ESCs [13,15,16,44] and, accordingly, can be
considered as having at least a decreased susceptibility
to ESCs.
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ESC resistance determinant (penA) and molecular
epidemiology
Overall, 76 (33.3%) isolates contained a penA mosaic
allele, and the MICs of ceftriaxone and cefixime for
these isolates ranged from 0.002-0.125 mg/L (mean
MIC: 0.032 mg/L) and <0.016 to 0.125 mg/L (mean
MIC: 0.064 mg/L), respectively. Thirteen isolates (5.7%)
contained a PBP2 A501V alteration and one (0.4%) a
PBP2 A501T alteration, and the MICs of ceftriaxone
and cefixime for these isolates ranged from 0.016 to
0.125 mg/L (mean MIC: 0.064 mg/L) and from <0.016
to 0.064 mg/L (mean MIC: 0.032 mg/L), respectively.
The NG-MAST STs, MICs of ESCs, and presence of the
main ESC resistance determinants (penA mosaic allele
and PBP2 A501-altered allele) in all isolates are summa-
rized in Table 2.
Briefly, twenty-eight (93.3%) of the 30 isolates with de-
creased susceptibility (MIC = 0.125 mg/L) to ceftriaxone
(n = 2), cefixime (n = 19) or both ESCs (n = 9) contained
a penA mosaic allele, and one (3.3%) contained an
A501V alteration in PBP2. Furthermore, 25 (83.3%) of
these 30 isolates belonged to NG-MAST ST1407.
In total, the 228 isolates were assigned to 66 different
NG-MAST STs. Thirty-four (51.5%) of these STs were
not previously described. The most prevalent ST was
ST1407 (25.4% of isolates), followed by ST2992 (7.5%),
ST1405 (5.3%), ST1861 (4.4%), ST8392 (3.5%), and
ST8379 (3.5%) (Table 2). The proportion of isolates of
the most prevalent ST (ST1407) rapidly and significantly
increased from none in 2010, to 12 (13.0%) in 2011 and
finally to 46 (42.6%) in 2012 (P < 0.05). All ST1407 iso-
lates (100%) contained a mosaic penA allele (Table 2).
Discussion
The present study describes the first internationally re-
ported gonococcal AMR data in nearly four decades
and the first molecular characterization of N. gonor-
rhoeae isolates in Poland. Despite the global concern of
multidrug-resistant and possibly future untreatable gon-
orrhoea [5], the last published AMR data, with exception
of β-lactamase production [36,37], for gonococcal iso-
lates from Poland are from the mid-to late-1970s and
only published in Polish [34,35,38]. Furthermore, the
susceptibility to internationally frequently used antimi-
crobials such as ceftriaxone, cefixime, spectinomycin,
ciprofloxacin, and azithromycin has never been assessed.
Overall, high prevalence of resistance, including multi-
drug resistance, was observed for internationally previ-
ously recommended antimicrobials such as ciprofloxacin
(60.5%), tetracycline (43.0%), and penicillin G (22.4%),
and the latter remains nationally recommended for
treatment of gonorrhoea in Poland [32,33]. Five per cent
(range: 2.2%-21.4% during 2010-2012) of the gonococcal
isolates in Poland were β-lactamase producing, which is
substantially higher than the previously reported preva-
lence of 0.8% (range: 0-1.1%) during 2006-2009 [37].
The prevalence of resistance to azithromycin was also
relatively high (8.8%). Similar levels of resistance to cip-
rofloxacin, tetracycline, penicillin G and azithromycin
have been described from many other countries in Eur-
ope and basically worldwide [3-6,20-22,45,46], and none
of these antimicrobials should be recommended for em-
piric first-line antimicrobial monotherapy in Poland or
in many other countries globally. Accordingly, it is essen-
tial to promptly revise and strictly implement an up-to-date
treatment guideline for gonorrhoea in Poland. The results
of the present study provide a strong evidence base for
this revision of the Polish treatment guidelines, which
has been initiated. No isolates with resistance (MIC >
0.125 mg/L) to ceftriaxone or cefixime were found.
However, worryingly the proportion of isolates displaying
decreased susceptibility to ESCs (MIC = 0.125 mg/L),
Table 1 Antimicrobial susceptibility of 228 Neisseria gonorrhoeae isolates from Poland in 2010-2012
Antimicrobial (Breakpoints (mg/L)) Susceptible no. (%) Intermediate susceptible no. (%) Resistant no. (%)
2010 2011 2012 2010 2011 2012 2010 2011 2012
Ceftriaxone (S ≤ 0.125, I = NA, R > 0.125)* 28 (100) 92 (100) 108 (100) NA NA NA 0 0 0
Cefixime (S ≤ 0.125, I = NA, R > 0.125)* 28 (100) 92 (100) 108 (100) NA NA NA 0 0 0
Spectinomycin (S ≤ 64, I = NA, R > 64)* 28 (100) 92 (100) 108 (100) NA NA NA 0 0 0
Azithromycin (S ≤ 0.25, I = 0.5, R > 0.5)* 23 (82.1) 60 (65.2) 63 (58.3) 2 (7.1) 26 (28.3) 34 (31.5) 3 (10.7) 6 (6.5) 11 (10.2)
Penicillin G (S ≤ 0.064, I = 0.125-1.0, R > 1.0)* 3 (10.7) 7 (7.6) 3 (2.8) 17 (60.7) 72 (78.3) 75 (69.4) 8 (28.6) 13 (14.1) 30 (27.8)
Tetracycline (S ≤ 0.5, I = 1.0, R > 1.0)* 12 (42.9) 31 (33.7) 26 (24.1) 4 (14.3) 26 (28.3) 31 (28.7) 12 (42.9) 35 (38.0) 51 (47.2)
Ciprofloxacin (S ≤ 0.032, I = 0.064, R > 0.064)* 10 (35.7) 46 (50) 34 (31.5) 0 0 0 18 (64.3) 46 (50) 74 (68.5)
Gentamicin** MIC range: 0.032-8 mg/L; MIC50: 4 mg/L; and MIC90: 4 mg/L
β-lactamase production 2010: 6 (21.4%) ; 2011: 2 (2.2%); and 2012: 4 (3.7%)
NA, not applicable.
*Breakpoints for susceptible (S ≤ x mg/L) and resistant (R > y mg/L) according to The European Committee on Antimicrobial Susceptibility Testing
(EUCAST; www.eucast.org).
**Breakpoints not stated by any organization.
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which have previously resulted in gonorrhoea ESC
treatment failures [13,15,16,44], rapidly increased from
none in 2010, to 7.6% in 2011, and 13.9% in 2012.
Ninety-three per cent of these isolates contained a mo-
saic penA allele, which has been associated with de-
creased susceptibility or resistance to ESCs in many
countries [3,5,9-19,24-30]. It is crucial to continuously
follow the spread of gonococcal strains with multidrug
resistance and decreased susceptibility or future re-
sistance to ESCs in Poland. Accordingly, gonococcal
AMR (ideally also treatment failures) will be surveyed
annually in Poland (isolates are prospectively col-
lected) and preparations for joining the European
Gonococcal Antimicrobial Surveillance Programme
(Euro-GASP) [46,47], which acts in the EU/EEA, have
been initiated.
Table 2 Neisseria gonorrhoeae multiantigen sequence typing (NG-MAST) STs, minimum inhibitory concentrations




Drug No. of isolates with MIC (mg/L): penA
alterationa
≤0.016 0.032 0.064 0.125 0.25
1407 (58) IX 4 30 24 58 (100%) mosaic
TX 4 18 27 9
2992 (17) IX 17 17 (100%) WT
TX 17
1405 (12) IX 3 8 1 12 (100%) A501V
TX 2 6 4
1861 (10) IX 5 5 10 (100%) WT
TX 1 4 5
8392 (8)b IX 8 8 (100%) WT
TX 8
8379 (8)b IX 8 8 (100%) WT
TX 6 2
8391 (7)b IX 7 7 (100%) WT
TX 7
5421 (7) IX 7 7 (100%) WT
TX 7
8370 (6) IX 6 6 (100%) WT
TX 6
1478 (5) IX 5 5 (100%) WT
TX 5
7674 (5) IX 5 5 (100%) WT
TX 5
21 (5) IX 4 1 5 (100%) WT
TX 2 1 2
STs with 2-4 isolates (42)c IX 30 6 4 2 8 (19%) mosaic; 34 (81%) WT
TX 31 6 5
Unique STs (38)d IX 28 3 5 2 10 (26%) mosaic; 1 (2.6%) A501V; 1 (2.6%) A501T; 26 (68%) WT
TX 28 4 4 2
NG-MAST, Neisseria gonorrhoeae multiantigen sequence typing; ST, sequence type; MIC, minimum inhibitory concentration; IX, cefixime; TX, ceftriaxone;
WT, wild type.
aPresence of penA mosaic allele or alteration of amino acid A501 in the penicillin-binding protein 2, which both have been associated with decreased susceptibility
to extended-spectrum cephalosporins [5].
bNovel sequence types found in the present study.
cSTs represented by 2-4 isolates; 225 (4), 8387 (4)b, 8373 (3)b, 298 (3), 1340 (3), 8385 (3)b, 4758 (3), 735 (2), 2226 (2), 5004 (2), 8377 (2)b, 8378 (2)b, 8393 (2)b,
8394 (2)b, and 8399 (2)b.
dUnique STs represented by single isolates.
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Using NG-MAST, the present study identified a diversi-
fied gonococcal population in Poland during 2010-2012,
with 66 different NG-MAST STs among the 228 isolates.
ST1407 (25.4% of all isolates) was the most frequent ST
and also significantly increased from 2010 (0%) to 2012
(42.6%). Of the ST1407 isolates, 15.5% displayed decreased
susceptibility to ceftriaxone and 41.4% to cefixime, and all
contained a mosaic penA allele. NG-MAST ST1407 has
been previously shown to account for most of the de-
creased susceptibility or resistance to ESCs in Europe and
to be responsible for treatment failures with cefixime in
Norway [11], Austria [10], France [9] and Canada [13], as
well as with ceftriaxone in Slovenia [16]. The high number
of unique STs (n = 38) and novel STs (n = 34), which were
identified in Poland, may be associated with suboptimal
diagnostics (only random gonorrhoea patients and/or iso-
lates are identified), contact tracing (sexual contacts hav-
ing the identical ST are not traced) and epidemiological
surveillance (sexual transmission chains spreading a single
ST are not identified or followed-up), locally evolved STs
(novel STs because no NG-MAST studies have been previ-
ously performed in the country) or STs imported from
abroad. However, some main ST clusters caused by clonal
spread of, e.g., ST1407 (n = 58), ST 2992 (n = 17), ST1405
(n = 12), and ST1861 (n = 10) were identified, which indi-
cate some larger sexual transmission chains.
The reported incidences of gonorrhoea in Poland (<2
cases per 100,000 inhabitants annually during last dec-
ade) have been substantially lower than in neighbouring
countries/regions, for example, in 2011 in Belarus (33.4),
Kaliningrad Oblast (27.5), Ukraine (20.1), Lithuania
(6.7), Czech Republic (6.7) and Slovakia (3.6) [2,47]. The
gonorrhoea incidence in Poland is likely underestimated,
due to suboptimal diagnostics (more sensitive methods
such as NAATs and/or culture need to be more fre-
quently used), access to appropriate diagnostics and lack
of screening of asymptomatic patients, and incomplete
case reporting (particularly among private health care
providers) as well as epidemiological surveillance.
Conclusion
N. gonorrhoeae isolates cultured in Poland in 2010-2012
showed a high genetic diversity and high levels of
resistance to antimicrobials internationally earlier rec-
ommended for gonorrhoea treatment, e.g., ciprofloxacin,
tetracycline, and penicillin G. No resistance, however,
relatively high and rapidly increasing levels of decreased
susceptibility (MIC = 0.125 mg/L) to ceftriaxone and to
cefixime were identified, which was mostly due to
the introduction of the internationally spread multidrug-
resistant NG-MAST ST1407 in Poland in 2011. It is es-
sential to promptly revise the gonorrhoea treatment
guidelines (which the present study provides an evidence
base for), improve the gonorrhoea laboratory diagnos-
tics, and implement quality assured surveillance of gono-
coccal AMR (ideally also treatment failures) in Poland.
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